{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:38:34Z","timestamp":1794746314331,"version":"4.9.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01823-6","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:38:04Z","timestamp":1759851484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6804-9586","authenticated-orcid":false,"given":"Raphaelle","family":"Caillierez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Leboullenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Besegher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"B\u00e9gard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Auger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude-Alain","family":"Maurage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Accart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Mortelecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elian","family":"Dupr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Danis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Landrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-4230","authenticated-orcid":false,"given":"Luc","family":"Bu\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0611-4167","authenticated-orcid":false,"given":"Morvane","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"6","key":"1823_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","volume":"12","author":"MG Spillantini","year":"2013","unstructured":"Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609\u201322. https:\/\/doi.org\/10.1016\/S1474-4422(13)70090-5.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1823_CR2","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1093\/brain\/awac229","volume":"145","author":"JA Tanner","year":"2022","unstructured":"Tanner JA, Iaccarino L, Edwards L, Asken BM, Gorno-Tempini ML, Kramer JH, et al. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer\u2019s disease. Brain. 2022;145(12):4489\u2013505. https:\/\/doi.org\/10.1093\/brain\/awac229.","journal-title":"Brain"},{"issue":"5","key":"1823_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362\u201381. https:\/\/doi.org\/10.1097\/NEN.0b013e31825018f7.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7662","key":"1823_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature. 2017;547(7662):185\u201390. https:\/\/doi.org\/10.1038\/nature23002.","journal-title":"Nature"},{"issue":"5","key":"1823_CR5","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1096\/fj.11-199851","volume":"26","author":"CA Lasagna-Reeves","year":"2012","unstructured":"Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer\u2019s disease. FASEB J. 2012;26(5):1946\u201359. https:\/\/doi.org\/10.1096\/fj.11-199851. doi: fj.11-199851 [pii].","journal-title":"FASEB J"},{"issue":"4","key":"1823_CR6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1823_CR7","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","volume":"52","author":"A Delacourte","year":"1999","unstructured":"Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer\u2019s disease. Neurology. 1999;52(6):1158\u201365.","journal-title":"Neurology"},{"issue":"1","key":"1823_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00401-019-02087-9","volume":"139","author":"M Colin","year":"2020","unstructured":"Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade JP, et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol. 2020;139(1):3\u201325. https:\/\/doi.org\/10.1007\/s00401-019-02087-9.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1823_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-018-1911-2","volume":"136","author":"JP Courade","year":"2018","unstructured":"Courade JP, Angers R, Mairet-Coello G, Pacico N, Tyson K, Lightwood D, et al. Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau. Acta Neuropathol. 2018;136(5):729\u201345. https:\/\/doi.org\/10.1007\/s00401-018-1911-2.","journal-title":"Acta Neuropathol"},{"key":"1823_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2024.149018","volume":"1840","author":"P Bhadane","year":"2024","unstructured":"Bhadane P, Roul K, Belemkar S, Kumar D. Immunotherapeutic approaches for Alzheimer\u2019s disease: exploring active and passive vaccine progress. Brain Res. 2024;1840: 149018. https:\/\/doi.org\/10.1016\/j.brainres.2024.149018.","journal-title":"Brain Res"},{"issue":"12","key":"1823_CR11","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","volume":"91","author":"JF Poduslo","year":"1994","unstructured":"Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci U S A. 1994;91(12):5705\u20139. https:\/\/doi.org\/10.1073\/pnas.91.12.5705.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1823_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13024-019-0340-6","volume":"14","author":"G Gallardo","year":"2019","unstructured":"Gallardo G, Wong CH, Ricardez SM, Mann CN, Lin KH, Leyns CEG, et al. Targeting tauopathy with engineered tau-degrading intrabodies. Mol Neurodegener. 2019;14(1):38. https:\/\/doi.org\/10.1186\/s13024-019-0340-6.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"1823_CR13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1084\/jem.20162125","volume":"214","author":"C Ising","year":"2017","unstructured":"Ising C, Gallardo G, Leyns CEG, Wong CH, Jiang H, Stewart F, et al. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med. 2017;214(5):1227\u201338. https:\/\/doi.org\/10.1084\/jem.20162125.","journal-title":"J Exp Med"},{"issue":"2","key":"1823_CR14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ymthe.2020.10.007","volume":"29","author":"MS Goodwin","year":"2021","unstructured":"Goodwin MS, Sinyavskaya O, Burg F, O\u2019Neal V, Ceballos-Diaz C, Cruz PE, et al. Anti-tau scFvs targeted to the cytoplasm or secretory pathway variably modify pathology and neurodegenerative phenotypes. Mol Ther. 2021;29(2):859\u201372. https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.007.","journal-title":"Mol Ther"},{"issue":"1","key":"1823_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-018-0585-2","volume":"6","author":"F Vitale","year":"2018","unstructured":"Vitale F, Giliberto L, Ruiz S, Steslow K, Marambaud P, d\u2019Abramo C. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol Commun. 2018;6(1):82. https:\/\/doi.org\/10.1186\/s40478-018-0585-2.","journal-title":"Acta Neuropathol Commun"},{"issue":"6428","key":"1823_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446\u20138. https:\/\/doi.org\/10.1038\/363446a0.","journal-title":"Nature"},{"key":"1823_CR17","doi-asserted-by":"publisher","first-page":"114726","DOI":"10.1016\/j.addr.2023.114726","volume":"195","author":"JY Kim","year":"2023","unstructured":"Kim JY, Sang Z, Xiang Y, Shen Z, Shi Y. Nanobodies: robust miniprotein binders in biomedicine. Adv Drug Deliv Rev. 2023;195:114726. https:\/\/doi.org\/10.1016\/j.addr.2023.114726.","journal-title":"Adv Drug Deliv Rev"},{"key":"1823_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978513","volume":"13","author":"F Zheng","year":"2022","unstructured":"Zheng F, Pang Y, Li L, Pang Y, Zhang J, Wang X, et al. Applications of nanobodies in brain diseases. Front Immunol. 2022;13: 978513. https:\/\/doi.org\/10.3389\/fimmu.2022.978513.","journal-title":"Front Immunol"},{"issue":"12","key":"1823_CR19","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1073\/pnas.0505379103","volume":"103","author":"E De Genst","year":"2006","unstructured":"De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A. 2006;103(12):4586\u201391. https:\/\/doi.org\/10.1073\/pnas.0505379103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"1823_CR20","doi-asserted-by":"publisher","first-page":"eadf3775","DOI":"10.1126\/sciadv.adf3775","volume":"9","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Lin Y, Krishnaswamy S, Pan R, Wu Q, Sandusky-Beltran LA, et al. Single-domain antibody-based noninvasive in vivo imaging of alpha-synuclein or tau pathology. Sci Adv. 2023;9(19):eadf3775. https:\/\/doi.org\/10.1126\/sciadv.adf3775.","journal-title":"Sci Adv"},{"key":"1823_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.09.019","volume":"243","author":"T Li","year":"2016","unstructured":"Li T, Vandesquille M, Koukouli F, Dudeffant C, Youssef I, Lenormand P, et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control Release. 2016;243:1\u201310. https:\/\/doi.org\/10.1016\/j.jconrel.2016.09.019.","journal-title":"J Control Release"},{"issue":"4","key":"1823_CR22","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.ymthe.2022.01.009","volume":"30","author":"C Danis","year":"2022","unstructured":"Danis C, Dupre E, Zejneli O, Caillierez R, Arrial A, Begard S, et al. Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol Ther. 2022;30(4):1484\u201399. https:\/\/doi.org\/10.1016\/j.ymthe.2022.01.009.","journal-title":"Mol Ther"},{"issue":"9","key":"1823_CR23","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1021\/acschemneuro.9b00217","volume":"10","author":"E Dupre","year":"2019","unstructured":"Dupre E, Danis C, Arrial A, Hanoulle X, Homa M, Cantrelle FX, et al. Single domain antibody fragments as new tools for the detection of neuronal Tau protein in cells and in mice studies. ACS Chem Neurosci. 2019;10(9):3997\u20134006. https:\/\/doi.org\/10.1021\/acschemneuro.9b00217.","journal-title":"ACS Chem Neurosci"},{"issue":"41","key":"1823_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300258120","volume":"120","author":"R Abskharon","year":"2023","unstructured":"Abskharon R, Pan H, Sawaya MR, Seidler PM, Olivares EJ, Chen Y, et al. Structure-based design of nanobodies that inhibit seeding of Alzheimer\u2019s patient-extracted tau fibrils. Proc Natl Acad Sci U S A. 2023;120(41): e2300258120. https:\/\/doi.org\/10.1073\/pnas.2300258120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1823_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41419-024-06927-9","volume":"15","author":"S Nair","year":"2024","unstructured":"Nair S, Jiang Y, Marchal IS, Chernobelsky E, Huang HW, Suh S, et al. Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defects. Cell Death Dis. 2024;15(7):543. https:\/\/doi.org\/10.1038\/s41419-024-06927-9.","journal-title":"Cell Death Dis"},{"issue":"6712","key":"1823_CR26","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1126\/science.adp5186","volume":"385","author":"J Benn","year":"2024","unstructured":"Benn J, Cheng S, Keeling S, Smith AE, Vaysburd MJ, Boken D, et al. Aggregate-selective removal of pathological tau by clustering-activated degraders. Science. 2024;385(6712):1009\u201316. https:\/\/doi.org\/10.1126\/science.adp5186.","journal-title":"Science"},{"key":"1823_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104249","volume":"84","author":"EE Congdon","year":"2022","unstructured":"Congdon EE, Pan R, Jiang Y, Sandusky-Beltran LA, Dodge A, Lin Y, et al. Single domain antibodies targeting pathological tau protein: influence of four IgG subclasses on efficacy and toxicity. EBioMedicine. 2022;84: 104249. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104249.","journal-title":"EBioMedicine"},{"key":"1823_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.sbi.2020.05.011","volume":"64","author":"SH Scheres","year":"2020","unstructured":"Scheres SH, Zhang W, Falcon B, Goedert M. Cryo-EM structures of tau filaments. Curr Opin Struct Biol. 2020;64:17\u201325. https:\/\/doi.org\/10.1016\/j.sbi.2020.05.011.","journal-title":"Curr Opin Struct Biol"},{"issue":"2","key":"1823_CR29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1021\/acs.jproteome.5b01001","volume":"15","author":"NR Barthelemy","year":"2016","unstructured":"Barthelemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, et al. Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res. 2016;15(2):667\u201376. https:\/\/doi.org\/10.1021\/acs.jproteome.5b01001.","journal-title":"J Proteome Res"},{"issue":"4","key":"1823_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3233\/JAD-150962","volume":"51","author":"NR Barthelemy","year":"2016","unstructured":"Barthelemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, et al. Differential mass spectrometry profiles of Tau protein in the cerebrospinal fluid of patients with Alzheimer\u2019s disease, progressive supranuclear palsy, and dementia with Lewy bodies. J Alzheimers Dis. 2016;51(4):1033\u201343. https:\/\/doi.org\/10.3233\/JAD-150962.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"1823_CR31","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1073\/pnas.97.10.5129","volume":"97","author":"M von Bergen","year":"2000","unstructured":"von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 2000;97(10):5129\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1823_CR32","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/j.1471-4159.2007.04834.x","volume":"103","author":"M Perez","year":"2007","unstructured":"Perez M, Santa-Maria I, Tortosa E, Cuadros R, Del Valle M, Hernandez F, et al. The role of the VQIVYK peptide in tau protein phosphorylation. J Neurochem. 2007;103(4):1447\u201360. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04834.x.","journal-title":"J Neurochem"},{"issue":"7993","key":"1823_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-023-06788-w","volume":"625","author":"S Lovestam","year":"2024","unstructured":"Lovestam S, Li D, Wagstaff JL, Kotecha A, Kimanius D, McLaughlin SH, et al. Disease-specific tau filaments assemble via polymorphic intermediates. Nature. 2024;625(7993):119\u201325. https:\/\/doi.org\/10.1038\/s41586-023-06788-w.","journal-title":"Nature"},{"key":"1823_CR34","doi-asserted-by":"publisher","unstructured":"Moutel S, Bery N, Bernard V, Keller L, Lemesre E, de Marco A, et al. NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife. 2016;5. https:\/\/doi.org\/10.7554\/eLife.16228.","DOI":"10.7554\/eLife.16228"},{"key":"1823_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658399","volume":"12","author":"T Weber","year":"2021","unstructured":"Weber T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front Immunol. 2021;12: 658399. https:\/\/doi.org\/10.3389\/fimmu.2021.658399.","journal-title":"Front Immunol"},{"key":"1823_CR36","doi-asserted-by":"publisher","unstructured":"Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA. Various AAV serotypes and their applications in gene therapy: an overview. Cells. 2023;12(5). https:\/\/doi.org\/10.3390\/cells12050785.","DOI":"10.3390\/cells12050785"},{"issue":"2","key":"1823_CR37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2353\/ajpath.2006.060002","volume":"169","author":"K Schindowski","year":"2006","unstructured":"Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, et al. Alzheimer\u2019s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169(2):599\u2013616. doi: 169\/2\/599 [pii].","journal-title":"Am J Pathol"},{"issue":"3","key":"1823_CR38","doi-asserted-by":"publisher","first-page":"976","DOI":"10.2353\/ajpath.2007.070345","volume":"171","author":"K Leroy","year":"2007","unstructured":"Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, et al. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol. 2007;171(3):976\u201392. https:\/\/doi.org\/10.2353\/ajpath.2007.070345. doi: ajpath.2007.070345 [pii].","journal-title":"Am J Pathol"},{"issue":"4","key":"1823_CR39","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/9780470942390.mo150068","volume":"5","author":"SM Holter","year":"2015","unstructured":"Holter SM, Garrett L, Einicke J, Sperling B, Dirscherl P, Zimprich A, et al. Assessing cognition in mice. Curr Protoc Mouse Biol. 2015;5(4):331\u201358. https:\/\/doi.org\/10.1002\/9780470942390.mo150068.","journal-title":"Curr Protoc Mouse Biol"},{"key":"1823_CR40","doi-asserted-by":"publisher","unstructured":"Gould TD. Mood and Anxiety-related Phenotypes in Mice: Characterization Using Behavioral Tests. Genes, Brain and Behavior. 2010;9(5):449-544. https:\/\/doi.org\/10.1111\/j.1601-183X.2010.00592.","DOI":"10.1111\/j.1601-183X.2010.00592"},{"issue":"6","key":"1823_CR41","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1109\/TMI.2010.2046908","volume":"29","author":"NJ Tustison","year":"2010","unstructured":"Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29(6):1310\u201320. https:\/\/doi.org\/10.1109\/TMI.2010.2046908.","journal-title":"IEEE Trans Med Imaging"},{"issue":"5","key":"1823_CR42","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1049\/iet-ipr.2011.0161","volume":"6","author":"P Coupe","year":"2012","unstructured":"Coupe P, Manjon JV, Robles M, Collins DL. Adaptive multiresolution non-local means filter for three-dimensional magnetic resonance image denoising. IET Image Proc. 2012;6(5):558\u201368. https:\/\/doi.org\/10.1049\/iet-ipr.2011.0161.","journal-title":"IET Image Proc"},{"issue":"1","key":"1823_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086576","volume":"9","author":"D Ma","year":"2014","unstructured":"Ma D, Cardoso MJ, Modat M, Powell N, Wells J, Holmes H, et al. Automatic structural parcellation of mouse brain MRI using multi-atlas label fusion. PLoS ONE. 2014;9(1): e86576. https:\/\/doi.org\/10.1371\/journal.pone.0086576.","journal-title":"PLoS ONE"},{"issue":"6","key":"1823_CR44","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.mri.2012.02.010","volume":"30","author":"J Bai","year":"2012","unstructured":"Bai J, Trinh TL, Chuang KH, Qiu A. Atlas-based automatic mouse brain image segmentation revisited: model complexity vs. image registration. Magn Reson Imaging. 2012;30(6):789\u201398. https:\/\/doi.org\/10.1016\/j.mri.2012.02.010.","journal-title":"Magn Reson Imaging"},{"issue":"4","key":"1823_CR45","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.neuroimage.2007.10.039","volume":"39","author":"S Chung","year":"2008","unstructured":"Chung S, Pelletier D, Sdika M, Lu Y, Berman JI, Henry RG. Whole brain voxel-wise analysis of single-subject serial DTI by permutation testing. Neuroimage. 2008;39(4):1693\u2013705. https:\/\/doi.org\/10.1016\/j.neuroimage.2007.10.039.","journal-title":"Neuroimage"},{"key":"1823_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1472-6750-9-14","volume":"9","author":"S Moutel","year":"2009","unstructured":"Moutel S, El Marjou A, Vielemeyer O, Nizak C, Benaroch P, Dubel S, et al. A multi-Fc-species system for recombinant antibody production. BMC Biotechnol. 2009;9:14. https:\/\/doi.org\/10.1186\/1472-6750-9-14.","journal-title":"BMC Biotechnol"},{"issue":"3","key":"1823_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ymthe.2005.10.008","volume":"13","author":"RL Klein","year":"2006","unstructured":"Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, Zweig RM. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther. 2006;13(3):517\u201327. https:\/\/doi.org\/10.1016\/j.ymthe.2005.10.008.","journal-title":"Mol Ther"},{"issue":"3","key":"1823_CR48","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.nurt.2007.05.011","volume":"4","author":"AL Alexander","year":"2007","unstructured":"Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurotherapeutics. 2007;4(3):316\u201329. https:\/\/doi.org\/10.1016\/j.nurt.2007.05.011.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1823_CR49","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1042\/BST0390874","volume":"39","author":"B Platt","year":"2011","unstructured":"Platt B, Welch A, Riedel G. FDG-PET imaging, EEG and sleep phenotypes as translational biomarkers for research in Alzheimer\u2019s disease. Biochem Soc Trans. 2011;39(4):874\u201380. https:\/\/doi.org\/10.1042\/BST0390874.","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"1823_CR50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00227819","volume":"84","author":"M Mercken","year":"1992","unstructured":"Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van de Voorde A, et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 1992;84(3):265\u201372.","journal-title":"Acta Neuropathol"},{"issue":"46","key":"1823_CR51","doi-asserted-by":"publisher","first-page":"32066","DOI":"10.1074\/jbc.M805300200","volume":"283","author":"S Jeganathan","year":"2008","unstructured":"Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Mandelkow EM, Mandelkow E. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J Biol Chem. 2008;283(46):32066\u201376. https:\/\/doi.org\/10.1074\/jbc.M805300200. M805300200 [pii].","journal-title":"J Biol Chem"},{"issue":"21","key":"1823_CR52","doi-asserted-by":"crossref","first-page":"9340","DOI":"10.1523\/JNEUROSCI.22-21-09340.2002","volume":"22","author":"B Allen","year":"2002","unstructured":"Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22(21):9340\u201351. doi: 22\/21\/9340 [pii].","journal-title":"J Neurosci"},{"issue":"6","key":"1823_CR53","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/brain\/awz100","volume":"142","author":"M Albert","year":"2019","unstructured":"Albert M, Mairet-Coello G, Danis C, Lieger S, Caillierez R, Carrier S, et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain. 2019;142(6):1736\u201350. https:\/\/doi.org\/10.1093\/brain\/awz100.","journal-title":"Brain"},{"issue":"1","key":"1823_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2051-5960-2-14","volume":"2","author":"S Dujardin","year":"2014","unstructured":"Dujardin S, Lecolle K, Caillierez R, Begard S, Zommer N, Lachaud C, et al. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun. 2014;2(1):14. https:\/\/doi.org\/10.1186\/2051-5960-2-14. doi: 2051-5960-2-14 [pii].","journal-title":"Acta Neuropathol Commun"},{"key":"1823_CR55","doi-asserted-by":"crossref","unstructured":"Verny M, Duyckaerts C, Agid Y, Hauw JJ. The significance of cortical pathology in progressive supranuclear palsy. Clinico-pathological data in 10 cases. Brain. 1996;119(Pt 4):1123\u201336.","DOI":"10.1093\/brain\/119.4.1123"},{"issue":"Pt 6","key":"1823_CR56","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/brain\/awm104","volume":"130","author":"DR Williams","year":"2007","unstructured":"Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson\u2019s syndrome. Brain. 2007;130(Pt 6):1566\u201376. https:\/\/doi.org\/10.1093\/brain\/awm104.","journal-title":"Brain"},{"key":"1823_CR57","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3389\/fnagi.2017.00440","volume":"9","author":"M Brendel","year":"2017","unstructured":"Brendel M, Schonecker S, Hoglinger G, Lindner S, Havla J, Blautzik J, et al. [(18)F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy. Front Aging Neurosci. 2017;9:440. https:\/\/doi.org\/10.3389\/fnagi.2017.00440.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"1823_CR58","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/jnc.15796","volume":"165","author":"RAW Radford","year":"2023","unstructured":"Radford RAW, Rayner SL, Szwaja P, Morsch M, Cheng F, Zhu T, et al. Identification of phosphorylated tau protein interactors in progressive supranuclear palsy (PSP) reveals networks involved in protein degradation, stress response, cytoskeletal dynamics, metabolic processes, and neurotransmission. J Neurochem. 2023;165(4):563\u201386. https:\/\/doi.org\/10.1111\/jnc.15796.","journal-title":"J Neurochem"},{"issue":"2","key":"1823_CR59","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/brain\/awx347","volume":"141","author":"TE Cope","year":"2018","unstructured":"Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, et al. Tau burden and the functional connectome in Alzheimer\u2019s disease and progressive supranuclear palsy. Brain. 2018;141(2):550\u201367. https:\/\/doi.org\/10.1093\/brain\/awx347.","journal-title":"Brain"},{"issue":"9","key":"1823_CR60","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jnen\/63.9.911","volume":"63","author":"Y Saito","year":"2004","unstructured":"Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, et al. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol. 2004;63(9):911\u20138.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"1823_CR61","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ana.24559","volume":"79","author":"DJ Irwin","year":"2016","unstructured":"Irwin DJ, Brettschneider J, McMillan CT, Cooper F, Olm C, Arnold SE, et al. Deep clinical and neuropathological phenotyping of Pick disease. Ann Neurol. 2016;79(2):272\u201387. https:\/\/doi.org\/10.1002\/ana.24559.","journal-title":"Ann Neurol"},{"issue":"2","key":"1823_CR62","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ymthe.2021.09.020","volume":"30","author":"E Leroux","year":"2022","unstructured":"Leroux E, Perbet R, Caillierez R, Richetin K, Lieger S, Espourteille J, et al. Extracellular vesicles: major actors of heterogeneity in tau spreading among human tauopathies. Mol Ther. 2022;30(2):782\u201397. https:\/\/doi.org\/10.1016\/j.ymthe.2021.09.020.","journal-title":"Mol Ther"},{"key":"1823_CR63","doi-asserted-by":"publisher","unstructured":"Hansson K, Dahlen R, Hansson O, Pernevik E, Paterson R, Schott JM, et al. Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. Clin Mass Spectrom. 2019;14 Pt B:74\u201382. https:\/\/doi.org\/10.1016\/j.clinms.2019.07.002.","DOI":"10.1016\/j.clinms.2019.07.002"},{"issue":"1","key":"1823_CR64","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40478-017-0489-6","volume":"5","author":"I Sotiropoulos","year":"2017","unstructured":"Sotiropoulos I, Galas MC, Silva JM, Skoulakis E, Wegmann S, Maina MB, et al. Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathol Commun. 2017;5(1):91. https:\/\/doi.org\/10.1186\/s40478-017-0489-6.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"1823_CR65","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12017-009-8099-5","volume":"12","author":"E Okun","year":"2010","unstructured":"Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med. 2010;12(2):164\u201378. https:\/\/doi.org\/10.1007\/s12017-009-8099-5.","journal-title":"Neuromolecular Med"},{"key":"1823_CR66","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fnins.2014.00235","volume":"8","author":"JP Fuller","year":"2014","unstructured":"Fuller JP, Stavenhagen JB, Teeling JL. New roles for Fc receptors in neurodegeneration-the impact on immunotherapy for Alzheimer\u2019s Disease. Front Neurosci. 2014;8:235. https:\/\/doi.org\/10.3389\/fnins.2014.00235.","journal-title":"Front Neurosci"},{"issue":"35","key":"1823_CR67","doi-asserted-by":"publisher","first-page":"21652","DOI":"10.1074\/jbc.M115.657924","volume":"290","author":"KE Funk","year":"2015","unstructured":"Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct therapeutic mechanisms of Tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J Biol Chem. 2015;290(35):21652\u201362. https:\/\/doi.org\/10.1074\/jbc.M115.657924.","journal-title":"J Biol Chem"},{"issue":"1","key":"1823_CR68","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1038\/s41598-019-41105-4","volume":"9","author":"CR Andersson","year":"2019","unstructured":"Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, et al. Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcgamma-receptor binding and functional lysosomes. Sci Rep. 2019;9(1):4658. https:\/\/doi.org\/10.1038\/s41598-019-41105-4.","journal-title":"Sci Rep"},{"issue":"44","key":"1823_CR69","doi-asserted-by":"publisher","first-page":"11869","DOI":"10.1523\/JNEUROSCI.3647-07.2007","volume":"27","author":"CL Mac Donald","year":"2007","unstructured":"Mac Donald CL, Dikranian K, Bayly P, Holtzman D, Brody D. Diffusion tensor imaging reliably detects experimental traumatic axonal injury and indicates approximate time of injury. J Neurosci. 2007;27(44):11869\u201376. https:\/\/doi.org\/10.1523\/JNEUROSCI.3647-07.2007.","journal-title":"J Neurosci"},{"key":"1823_CR70","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neurobiolaging.2015.12.001","volume":"39","author":"HE Holmes","year":"2016","unstructured":"Holmes HE, Colgan N, Ismail O, Ma D, Powell NM, O\u2019Callaghan JM, et al. Imaging the accumulation and suppression of tau pathology using multiparametric MRI. Neurobiol Aging. 2016;39:184\u201394. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.12.001.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1823_CR71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59\u201365. https:\/\/doi.org\/10.1038\/nbt.1515.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"1823_CR72","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/mt.2011.34","volume":"19","author":"H Fu","year":"2011","unstructured":"Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther. 2011;19(6):1025\u201333. https:\/\/doi.org\/10.1038\/mt.2011.34.","journal-title":"Mol Ther"},{"key":"1823_CR73","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/srep00700","volume":"2","author":"CA Lasagna-Reeves","year":"2012","unstructured":"Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2012;2:700. https:\/\/doi.org\/10.1038\/srep00700.","journal-title":"Sci Rep"},{"issue":"11","key":"1823_CR74","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/pro.3499","volume":"27","author":"G Ghag","year":"2018","unstructured":"Ghag G, Bhatt N, Cantu DV, Guerrero-Munoz MJ, Ellsworth A, Sengupta U, et al. Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior. Protein Sci. 2018;27(11):1901\u20139. https:\/\/doi.org\/10.1002\/pro.3499.","journal-title":"Protein Sci"},{"issue":"3","key":"1823_CR75","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-200808","volume":"80","author":"MD Devous Sr","year":"2021","unstructured":"Devous MD Sr, Fleisher AS, Pontecorvo MJ, Lu M, Siderowf A, Navitsky M, et al. Relationships between cognition and neuropathological Tau in Alzheimer\u2019s disease assessed by 18F Flortaucipir PET. J Alzheimers Dis. 2021;80(3):1091\u2013104. https:\/\/doi.org\/10.3233\/JAD-200808.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1823_CR76","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1038\/s41467-021-26584-2","volume":"12","author":"GG Moreira","year":"2021","unstructured":"Moreira GG, Cantrelle FX, Quezada A, Carvalho FS, Cristovao JS, Sengupta U, et al. Dynamic interactions and Ca(2+)-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding. Nat Commun. 2021;12(1):6292. https:\/\/doi.org\/10.1038\/s41467-021-26584-2.","journal-title":"Nat Commun"},{"issue":"5","key":"1823_CR77","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41594-018-0057-1","volume":"25","author":"SA Mok","year":"2018","unstructured":"Mok SA, Condello C, Freilich R, Gillies A, Arhar T, Oroz J, et al. Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol. 2018;25(5):384\u201393. https:\/\/doi.org\/10.1038\/s41594-018-0057-1.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"1823_CR78","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1038\/s41467-025-58383-4","volume":"16","author":"C Danis","year":"2025","unstructured":"Danis C, Dupre E, Bouillet T, Denechaud M, Lefebvre C, Nguyen M, et al. Inhibition of tau neuronal internalization using anti-tau single domain antibodies. Nat Commun. 2025;16(1):3162. https:\/\/doi.org\/10.1038\/s41467-025-58383-4.","journal-title":"Nat Commun"},{"issue":"4","key":"1823_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107163","volume":"300","author":"J Mortelecque","year":"2024","unstructured":"Mortelecque J, Zejneli O, Begard S, Simoes MC, ElHajjar L, Nguyen M, et al. A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered protein. J Biol Chem. 2024;300(4): 107163. https:\/\/doi.org\/10.1016\/j.jbc.2024.107163.","journal-title":"J Biol Chem"},{"key":"1823_CR80","doi-asserted-by":"publisher","unstructured":"Caillierez R, Begard S, Lecolle K, Deramecourt V, Zommer N, Dujardin S, et al. Lentiviral Delivery of the Human Wild-type Tau Protein Mediates a Slow and Progressive Neurodegenerative Tau Pathology in the Rat Brain. Mol Ther. 2013;21(7):1358-68. https:\/\/doi.org\/10.1038\/mt.2013.66.","DOI":"10.1038\/mt.2013.66"},{"key":"1823_CR81","doi-asserted-by":"publisher","unstructured":"Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neurosci. 2001;4(1):29-37. https:\/\/doi.org\/10.1038\/82868.","DOI":"10.1038\/82868"},{"key":"1823_CR82","doi-asserted-by":"publisher","unstructured":"Dujardin S, Begard S, Caillierez R, Lachaud C, Delattre L, Carrier S, et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One. 2014;9(6):e100760. https:\/\/doi.org\/10.1371\/journal.pone.0100760.","DOI":"10.1371\/journal.pone.0100760"},{"key":"1823_CR83","doi-asserted-by":"publisher","unstructured":"Perbet R, Zufferey V, Leroux E, Parietti E, Espourteille J, Culebras L, et al. Tau Transfer via Extracellular Vesicles Disturbs the Astrocytic Mitochondrial System. Cells. 2023;12(7). https:\/\/doi.org\/10.3390\/cells12070985.","DOI":"10.3390\/cells12070985"},{"key":"1823_CR84","doi-asserted-by":"publisher","unstructured":"McEwen E, Kedersha N, Song B, Scheuner D, Gilks N, Han A, et al. Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure. J Biol Chem. 2005;280(17):16925-33. https:\/\/doi.org\/10.1074\/jbc.M412882200.","DOI":"10.1074\/jbc.M412882200"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01823-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01823-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01823-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:38:06Z","timestamp":1759851486000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01823-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1823"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01823-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6671579\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with French and European Community rules. The experimental research was performed with the approval of an ethics committee (agreement APAFIS #43474\u20132023050714441306 v6) and follows European guidelines for the use of animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"E.D., C.D., I.L and L.B. are the inventors of a patent (WO2020\/120644A1) that covers the use of VHH Z70 and VHHs derived from it. The remaining authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}